基线MRI特征对肝细胞癌热消融治疗患者的预后价值
基于SORAMIC II期前瞻性随机试验中88例早期肝细胞癌热消融后接受索拉非尼或安慰剂治疗患者的基线及随访影像,评估基线MRI特征对至复发时间(TTR)和局部复发的预后价值。结果显示,肝胆期瘤周低信号是 multivariable 分析中唯一显著的复发风险因素(p=0.003),病灶直径大于3 cm是局部复发的唯一显著风险因素(22.2% vs. 4.5%,p=0.007)。
要点
- 肝胆期瘤周低信号是多变量分析中唯一显著的复发风险因素(p=0.003),可作为影像生物标志物。
- 病灶直径大于3 cm者局部复发率22.2%,显著高于≤3 cm者的4.5%(p=0.007)。
- 多发病灶(p=0.028)和肝胆期瘤周低信号(p=0.012)在单变量分析中与更短TTR显著相关。
核心结论
- 肝胆期瘤周低信号可作为影像生物标志物,用于识别早期肝细胞癌热消融后复发风险增高的患者。
研究设计与样本
- 研究基于SORAMIC II期前瞻性随机试验,纳入88例接受热消融后辅助索拉非尼或匹配安慰剂治疗的早期肝细胞癌患者的基线和随访影像。
- 评估的基线MRI特征包括:不典型强化(缺乏流入或流出)、病灶直径、肿瘤包膜、动脉期瘤周强化、瘤内脂肪、边缘不规则、卫星灶和肝胆期瘤周低信号。
- 采用单变量和多变量Cox比例风险模型评估上述特征对TTR和局部复发的预后价值。
关键影像表现/征象
- 基线MRI评估的特征包括不典型强化(缺乏流入或流出)、肿瘤包膜、动脉期瘤周强化、瘤内脂肪、边缘不规则、卫星灶及肝胆期瘤周低信号。
诊断标准与关键数值
- 随访期间30例患者诊断任何部位复发,中位TTR为16.4个月(95% CI,15 - NA)。
- 单变量分析中,多发病灶(p=0.028)和肝胆期瘤周低信号(p=0.012)与更短TTR显著相关;AFP > 15 mg/dL(p=0.084)和肝硬化病史(p=0.099)为边缘性非显著。
- 多变量分析中,肝胆期瘤周低信号是复发的唯一显著风险因素(p=0.003)。
- 132个接受热消融的病灶中11个(8.3%)诊断局部复发(邻近热消融瘢痕)。
- 局部复发的唯一显著风险因素为病灶直径大于3 cm(22.2% vs. 4.5%,p=0.007)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate prognostic value of baseline MRI features for time-to-recurrence (TTR) and local recurrence in patients with early hepatocellular carcinoma (HCC).
METHOD: Baseline and follow-up images of 88 patients treated with thermal ablation followed by adjuvant sorafenib or matching placebo due to HCC within the phase II prospective randomized trial (SORAMIC) were included. Baseline MRI images were evaluated in terms of atypical enhancement (lack of wash-in or wash-out), lesion diameter, tumor capsule, peritumoral enhancement on arterial phase, intratumoral fat, irregular margin, satellite lesions, and peritumoral hypointensity on hepatobiliary phase. Prognostic value of these features for TTR and local recurrence were assessed with univariable and multivariable Cox proportional hazard models.
RESULTS: Recurrence at any location was diagnosed during follow-up in 30 patients, and the median TTR was 16.4 (95% CI, 15 - NA) months. The presence of more than one lesion (p = 0.028) and peritumoral hypointensity on hepatobiliary phase images (p = 0.012) at baseline were significantly associated with shorter TTR in univariable analysis. AFP > 15 mg/dL (p = 0.084), and history of cirrhosis (p = 0.099) were marginally non-significant. Peritumoral hypointensity on hepatobiliary phase images was the only significant risk factor for recurrence in multivariable analysis (p = 0.003). Local recurrence (adjacent to thermal scar) was diagnosed in eleven (8.3%) out of 132 lesions that underwent thermal ablation. The only significant risk factor for local recurrence was a lesion diameter larger than 3 cm (22.2% vs. 4.5%, p = 0.007).
CONCLUSIONS: Peritumoral hypointensity on hepatobiliary phase can serve as imaging biomarker to identify increased recurrence risk in patients undergoing thermal ablation for early-stage HCC.
引用
- Öcal O, Schütte K, Malfertheiner P, et al. Prognostic value of baseline MRI features in patients treated with thermal ablation for hepatocellular carcinoma. Eur J Radiol. 2023. PMID: 37806190. doi:10.1016/j.ejrad.2023.111120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。